Creo Medical Group PLC Director/PDMR Shareholding (2492A)
December 22 2017 - 6:10AM
UK Regulatory
TIDMCREO
RNS Number : 2492A
Creo Medical Group PLC
22 December 2017
Creo Medical Group plc (the "Company")
Director/PDMR Dealing
The Company announces that it has received notice of exercise of
options ("Options") under the Company's EMI Share Option Scheme
from Steven Morris, Chief Operating Officer, a PDMR, to subscribe
for 115,000 Ordinary Shares of GBP0.001 each in the Company (the
"New Ordinary Shares"). The exercise price of the Options is 15.56
pence each.
Following the exercise of these Options Mr Morris will hold
115,000 Ordinary Shares in the Company representing approximately
0.1423 per cent. of the Company's issued share capital.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur on or around 3 January 2018.
Following the issue of the New Ordinary Shares the Company's
total issued share capital will consist of 80,826,745 Ordinary
Shares. The Company does not hold any Ordinary Shares in Treasury.
Therefore, following the issue of the New Ordinary Shares the total
number of voting rights in the Company is 80,826,745. This figure
may be used by Shareholders as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or change to their interest in, the Company under the
FCA's Disclosure Guidance and Transparency Rules.
Template for notification and public disclosure of transactions
by persons discharging managerial responsibilities and persons
closely associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------
a) Name Steven Morris
--- ------------------------- --------------------------------
2 Reason for the notification
--- -----------------------------------------------------------
a) Position/status Chief Operating Officer
--- ------------------------- --------------------------------
b) Initial notification Initial
/Amendment
--- ------------------------- --------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- -----------------------------------------------------------
a) Name Creo Medical Group plc
--- ------------------------- --------------------------------
b) LEI 213800H188ZDCWWXFA21
--- ------------------------- --------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------------
a) Description of
the financial Ordinary shares of GBP0.001
instrument, type each
of instrument
Identification GB00BZ1BLL44
code
--- ------------------------- --------------------------------
b) Nature of the Exercise of shares options
transaction
--- ------------------------- --------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
----------------- ----------
Exercise of
shares options
at 15.56p per
share 115,000
----------------- ----------
--- ------------------------- --------------------------------
d) Aggregated information
- Aggregated volume
Weighted average price of
15.56 per share
- Price
--- ------------------------- --------------------------------
e) Date of the transaction 22 December 2017
--- ------------------------- --------------------------------
f) Place of the transaction Off Market
--- ------------------------- --------------------------------
Contacts
Creo Medical: Cenkos: FTI Consulting:
Richard Rees Camilla Hume/Mark Brett Pollard
+44 (0)129 160 6005 Connelly (NOMAD) / Mo Noonan
richard.rees@creomedical.com Michael Johnson +44 (0)203 727
/ Russell Kerr 1000
(Sales) creo@fticonsulting.com
+44 (0)207 397
8900
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and radiowave energy to surgical endoscopy. Creo
has developed CROMA, an electrosurgical platform that combines
bipolar radiofrequency for precise localised cutting and microwave
for controlled coagulation. This technology provides physicians
with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring the CROMA surgical system to
market through a suite of medical instruments which the Company has
designed, initially for GI therapeutic endoscopy, an area with high
unmet needs. The CROMA system will be developed further for
bronchoscopy and laparoscopy procedures. The Company believes its
technology can impact the landscape of surgery and endoscopy by
providing safer, less-invasive and more cost-efficient option of
treatment.
For more information about Creo Medical please see our website,
www.creomedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFIFFELFFID
(END) Dow Jones Newswires
December 22, 2017 07:10 ET (12:10 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024